- Home
- CRMD vs TBPH Comparison
CRMD vs TBPH Comparison
Compare CRMD & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- TBPH
- Stock Information
- Founded
- CRMD 2006
- TBPH 2013
- Country
- CRMD United States
- TBPH United States
- Employees
- CRMD N/A
- TBPH N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- CRMD Health Care
- TBPH Health Care
- Exchange
- CRMD Nasdaq
- TBPH Nasdaq
- Market Cap
- CRMD 464.7M
- TBPH 464.5M
- IPO Year
- CRMD 2010
- TBPH N/A
- Fundamental
- Price
- CRMD $8.50
- TBPH $9.30
- Analyst Decision
- CRMD Strong Buy
- TBPH Buy
- Analyst Count
- CRMD 6
- TBPH 3
- Target Price
- CRMD $14.50
- TBPH $11.33
- AVG Volume (30 Days)
- CRMD 2.6M
- TBPH 224.8K
- Earning Date
- CRMD 05-08-2025
- TBPH 05-12-2025
- Dividend Yield
- CRMD N/A
- TBPH N/A
- EPS Growth
- CRMD N/A
- TBPH N/A
- EPS
- CRMD N/A
- TBPH N/A
- Revenue
- CRMD $43,472,170.00
- TBPH $64,381,000.00
- Revenue This Year
- CRMD $207.65
- TBPH $51.09
- Revenue Next Year
- CRMD $50.13
- TBPH N/A
- P/E Ratio
- CRMD N/A
- TBPH N/A
- Revenue Growth
- CRMD N/A
- TBPH 12.12
- 52 Week Low
- CRMD $3.61
- TBPH $7.44
- 52 Week High
- CRMD $13.85
- TBPH $10.90
- Technical
- Relative Strength Index (RSI)
- CRMD 57.04
- TBPH 58.45
- Support Level
- CRMD $6.32
- TBPH $8.44
- Resistance Level
- CRMD $7.71
- TBPH $8.82
- Average True Range (ATR)
- CRMD 0.49
- TBPH 0.45
- MACD
- CRMD 0.32
- TBPH 0.08
- Stochastic Oscillator
- CRMD 97.64
- TBPH 94.70
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).